Timberlyne Therapeutics Secures $180 Million in Series A Funding to Advance its Anti-CD38 Antibody, CM313, for Underserved Medical Needs “`

5aef9d2c3a1197e2da90245db0f230e1 1 Timberlyne Therapeutics Launches with a $180 Million Series A Financing to Advance CM313, a Potentially Best-in-Class Anti-CD38 Monoclonal Antibody, for Diseases of High Unmet Medical Needs

Mountainfield Venture Partners, a biopharmaceutical company creation firm, collaborated with Keymed Biosciences to establish Timberlyne Therapeutics, securing global development and commercial rights outside of greater China for CM313.

Abingworth, Bain Capital Life Sciences, and Venrock Healthcare Capital Partners co-led the financing round.

SAN DIEGO, Jan. 9, 2025 — Timberlyne Therapeutics, a clinical-stage biopharmaceutical company specializing in novel therapies for autoimmune disorders, announced the completion of a $180 million Series A financing round to advance CM313, a potentially leading monoclonal antibody targeting CD38, for diseases with significant unmet medical needs. The funding round was led by Abingworth, Bain Capital Life Sciences, and Venrock Healthcare Capital Partners, with participation from Boyu Capital, Lilly Asia Ventures, Braidwell LP, and 3H Health Investment. Timberlyne Therapeutics was founded by Mountainfield Venture Partners, a biopharma company creation firm, in partnership with Keymed Biosciences.

Timberlyne secured exclusive worldwide development and commercialization rights for CM313, excluding greater China, from Keymed Biosciences, a prominent drug discovery and development company. The licensing agreement includes an undisclosed upfront payment for Keymed, along with future milestone payments, royalties on potential net sales, and equity in Timberlyne. Keymed retains development and commercialization rights within greater China.

CM313 is an IgG1 monoclonal antibody with enhanced complement-dependent cytotoxicity. It has undergone clinical trials for various conditions, including immune thrombocytopenic purpura, systemic lupus erythematosus, and relapsed/refractory multiple myeloma, showing potentially best-in-class properties. A clinical study published in the New England Journal of Medicine demonstrated CM313’s therapeutic potential, achieving a 95% response rate in patients with treatment-resistant Immune Thrombocytopenia.

About Timberlyne Therapeutics

Timberlyne Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing transformative therapies for significant unmet medical needs. Timberlyne’s main program is CM313, an IgG1 monoclonal antibody with enhanced complement-dependent cytotoxicity targeting CD38. By targeting CD38, highly expressed on plasma cells, NK cells, and other immune cells, CM313 modulates multiple immune cell types, resulting in rapid and sustained responses across various autoimmune diseases and cancers.

About Keymed Biosciences

Keymed Biosciences Inc. (HKEX: 02162) addresses critical unmet clinical needs, providing high-quality, affordable, and innovative therapies for patients domestically and internationally. Founded by medical and scientific experts from leading universities with extensive experience in translating scientific achievements into commercial success globally, Keymed’s core leadership team includes the inventors of the first PD-1 antibody drugs approved in the United States and China. The Company listed on the Hong Kong Stock Exchange’s main board on July 8, 2021.

To optimize research and discovery, we have established a fully integrated platform encompassing all key aspects of biologic drug development, including target validation, lead molecule discovery and optimization, preclinical evaluation, process development, translational research, clinical development, and manufacturing. This integrated approach allows for rapid and cost-effective identification, development, and advancement of our diverse pipeline of innovative antibody-based therapies, including monoclonal antibodies, antibody drug conjugates (ADCs), and bispecific antibodies.

About Mountainfield Venture Partners

Mountainfield Venture Partners is a biopharmaceutical company creation firm that establishes new companies around development-stage drug candidates with the potential to revolutionize patient care. We build companies around in-licensed drug candidates, exceptional leadership teams, and syndicated capital from top-tier life science investors. We also develop the strategy and operations for our companies, drawing on our extensive experience in biopharmaceutical leadership and operational roles across various organizations, from small start-ups to multinational pharmaceutical companies.

Contacts

For Mountainfield Venture Partners:

For Media:

Timberlyne Therapeutics logo

SOURCE Timberlyne Therapeutics

“`

elong